I
Isamu Okamoto
Researcher at Kyushu University
Publications - 458
Citations - 25482
Isamu Okamoto is an academic researcher from Kyushu University. The author has contributed to research in topics: Lung cancer & Epidermal growth factor receptor. The author has an hindex of 64, co-authored 413 publications receiving 19982 citations. Previous affiliations of Isamu Okamoto include Emory University & Kumamoto University.
Papers
More filters
Journal ArticleDOI
Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer
Nobuyuki Yamamoto,Hideyuki Harada,Isamu Okamoto,Noriyuki Masuda,Kazushige Hayakawa,Miyako Satouchi,Toshinori Soejima,Makoto Nishio,Takuyo Kozuka,Koji Takeda,Masahiro Tanaka,Takashi Seto,Tomonari Sasaki,Hiroshi Tsubouchi,Yasuyuki Kakurai,Yasumasa Nishimura,Kazuhiko Nakagawa +16 more
TL;DR: In this paper, the authors evaluated the tolerability and efficacy of nimotuzumab, a humanized IgG1 monoclonal anti-epidermal growth factor receptor antibody, with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small-cell lung cancer.
Journal ArticleDOI
Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer.
Tateaki Naito,Takashi Seto,Koji Takeda,Koichi Goto,Isamu Okamoto,Kazuhiko Nakagawa,Taro Ohba,Haruyasu Murakami,Toshiaki Takahashi,Takeharu Yamanaka,Nobuyuki Yamamoto +10 more
TL;DR: S-1 plus leucovorin combination therapy demonstrated promising efficacy and an acceptable toxicity profile in previously treated patients with NSCLC.
Journal ArticleDOI
A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L).
Takashi Seto,Koichi Azuma,Takeharu Yamanaka,Shunichi Sugawara,Hiroshige Yoshioka,Akira Ono,Shinji Atagi,Yasuo Iwamoto,Hidetoshi Hayashi,Isamu Okamoto,Hideo Saka,Mitsuoka Shigeki,Daichi Fujimoto,Kazumi Nishino,Atsushi Horiike,Haruko Daga,Takashi Sone,Nobuyuki Yamamoto,Kazuhiko Nakagawa,Yoichi Nakanishi +19 more
TL;DR: Two continuous maintenance therapies demonstrated the prolongation of survival for advanced nSQ-NSCLC through the use of Pem after Pem+Platinum and Bev after Bev+Plt-doublet.
Journal ArticleDOI
Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004).
TL;DR: In this article, the authors focus on the intracranial response to ICI therapy combined with platinum-based chemotherapy in patients with untreated brain metastases derived from NSCLC.
Journal ArticleDOI
Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study
Yukio Hosomi,Takashi Seto,Makoto Nishio,Koichi Goto,H. Yamamoto,Isamu Okamoto,Kosei Tajima,Yusuke Kajihara,Nobuyuki Yamamoto +8 more
TL;DR: An exploratory analysis investigating the impact of baseline pleural/pericardial effusion (PPE) on patient outcomes is presented.